Farah Mushtaq, MD
Endocrinology, Diabetes & Metabolism · Katy, TXNPI 1669727228
Payments from drug & device makers
Across 329 payments — averaging $17.62 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Amgen$672
- Sanofi-aventis U.S. LLC$616
- Dexcom, Inc.$605
- Abbott$571
- Novo Nordisk$386
- Boehringer Ingelheim$360
- plus $3K from 30 others
What the payments were for
- Food & beverage$5,799100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Amgen(2 entities) | 37 | $672 |
| Sanofi-aventis U.S. LLC | 35 | $616 |
| Dexcom, Inc. | 29 | $605 |
| Abbott | 32 | $571 |
| Novo Nordisk | 24 | $386 |
| Boehringer Ingelheim | 19 | $360 |
| Lilly USA, LLC | 20 | $316 |
| AbbVie | 17 | $259 |
| Medtronic(2 entities) | 15 | $202 |
| AstraZeneca | 9 | $133 |
| Merck | 9 | $129 |
| Radius Health, Inc. | 4 | $124 |
| Pfizer | 7 | $117 |
| Sanofi | 6 | $117 |
| Bayer | 6 | $113 |
| Xeris Pharmaceuticals, Inc. | 5 | $107 |
| Novartis | 6 | $101 |
| Amarin Pharma, Inc. | 6 | $85 |
| BETA Bionics, Inc. | 3 | $85 |
| Johnson & Johnson | 5 | $76 |
| Regeneron Healthcare Solutions, Inc. | 4 | $72 |
| Insulet Corporation | 3 | $68 |
| Corcept Therapeutics | 4 | $64 |
| BD | 4 | $59 |
| Lifescan, Inc. | 4 | $54 |
| Averitas Pharma Inc. | 2 | $51 |
| IBSA Pharma Inc. | 3 | $50 |
| RGH Enterprises LLC | 1 | $40 |
| Tandem Diabetes Care, Inc. | 2 | $38 |
| Shire North American Group Inc | 2 | $30 |
| Sequel Med Tech, LLC | 1 | $21 |
| Kyowa Kirin, Inc. | 1 | $17 |
| Ascendis Pharma Endocrinology Inc | 1 | $17 |
| Ultragenyx Pharmaceutical Inc. | 1 | $16 |
| GRT US Holding, Inc. | 1 | $15 |
| Amneal Pharmaceuticals LLC | 1 | $14 |
How this compares
$5,799 in reported general payments places this provider in the 55th percentile of 658 endocrinology, diabetes & metabolism providers in Texas.
See all endocrinology, diabetes & metabolism providers in Texas →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| MounjaroTirzepatide | 219 | $259,498 |
| JardianceEmpagliflozin | 360 | $240,688 |
| TrulicityDulaglutide | 134 | $141,230 |
| OzempicSemaglutide | 103 | $138,166 |
| Tresiba Flextouch U-200Insulin Degludec | 65 | $65,120 |
| JanuviaSitagliptin Phosphate | 58 | $46,886 |
| Lantus SolostarInsulin Glargine,hum.Rec.Anlog | 259 | $40,565 |
| Tresiba Flextouch U-100Insulin Degludec | 79 | $38,568 |
| FarxigaDapagliflozin Propanediol | 31 | $32,168 |
| Toujeo SolostarInsulin Glargine,hum.Rec.Anlog | 52 | $24,588 |
| SynjardyEmpagliflozin/Metformin Hcl | 24 | $22,399 |
| Toujeo Max SolostarInsulin Glargine,hum.Rec.Anlog | 22 | $22,354 |
| SynthroidLevothyroxine Sodium | 253 | $15,923 |
| Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog | 33 | $15,785 |
| Synjardy XrEmpagliflozin/Metformin Hcl | 20 | $13,453 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Lilly USA, LLCMounjaro, Trulicity, Humulin 70-30 | $316 | $403,020367 claims |
| Boehringer IngelheimJardiance, Synjardy, Synjardy Xr, Tradjenta | $360 | $289,217427 claims |
| Novo NordiskOzempic, Rybelsus, Novolog | $386 | $154,761154 claims |
| MerckJanuvia | $129 | $46,88658 claims |
| AstraZenecaFarxiga | $133 | $32,16831 claims |
| AbbVieSynthroid | $259 | $15,923253 claims |
| Sanofi-aventis U.S. LLCLantus | $616 | $5,22846 claims |
| Amneal Pharmaceuticals LLCLevothyroxine Sodium | $14 | $4,069617 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 55th percentile of 658 endocrinology, diabetes & metabolism providers in Texas.
Other endocrinology, diabetes & metabolism in Katy
- Julio RosenstockDallas$24.9M
- Michelle WelchShavano Park$17.3M
- Maria CabanillasHouston$16.4M
- Sumana GangiMesquite$13.2M
- Damaris VegaHouston$12.3M
- Mark KipnesSan Antonio$10.3M
- Amer Al KaradshehHouston$8.8M
- Ildiko LingvayDallas$8.2M
- Eduardo LunaEdinburg$7.6M
- Thomas BlevinsAustin$7.4M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.